Neurocardiac pathologies associated with potassium channelopathies
Epilepsia · 2024
DOI: 10.1111/epi.18066 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Epilepsia, 2024. Verfasst von Veronica Singh und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, SUNY Upstate Medical University, Syracuse, New York, USA. Hauptthemen laut MEDLINE: Channelopathies, Epilepsy. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
Voltage‐gated potassium channels are expressed throughout the human body and are essential for physiological functions. These include delayed rectifiers, A‐type channels, outward rectifiers, and inward rectifiers. They impact electrical function in the heart (repolarization) and brain (repolarization and stabilization of the resting membrane potential). KCNQx and KCNHx encode K v 7.x and K v 11.x proteins, which form delayed rectifier potassium channels. KCNQx and KCNHx channelopathies are associated with both cardiac and neuronal pathologies. These include electrocardiographic abnormalities, cardiac arrhythmias, sudden cardiac death (SCD), epileptiform discharges, seizures, bipolar disorder, and sudden unexpected death in epilepsy (SUDEP). Due to the ubiquitous expression of KCNQx and KCNHx channels, abnormalities in their function can be particularly harmful, increasing the risk of sudden death. For example, KCNH2 variants have a dual role in both cardiac and neuronal pathologies, whereas KCNQ2 and KCNQ3 variants are associated with severe and refractory epilepsy. Recurrent and uncontrolled seizures lead to secondary abnormalities, which include autonomics, cardiac electrical function, respiratory drive, and neuronal electrical activity. Even with a wide array of anti‐seizure therapies available on the market, one‐third of the more than 70 million people worldwide with epilepsy have uncontrolled seizures (i.e., intractable/drug‐resistant epilepsy), which negatively impact neurodevelopment and quality of life. To capture the current state of the field, this review examines KCNQx and KCNHx expression patterns and electrical function in the brain and heart. In addition, it discusses several KCNQx and KCNHx variants that have been clinically and electrophysiologically characterized. Because these channel variants are associated with multi‐system pathologies, such as epileptogenesis, K v 7 channel modulators provide a potential anti‐seizure therapy, particularly for people with intractable epilepsy. Ultimately an increased understanding of the role of K v channels throughout the body will fuel the development of innovative, safe, and effective therapies for people at a high risk of sudden death (SCD and SUDEP).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, SUNY Upstate Medical University, Syracuse, New York, USA.
ORCID-Profile: Veronica Singh, David S Auerbach
Förderung
- NINDS NIH HHS
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Singh, V., & Auerbach, D. S. (2024). Neurocardiac pathologies associated with potassium channelopathies. Epilepsia. https://doi.org/10.1111/epi.18066
Vancouver
Singh V, Auerbach DS. Neurocardiac pathologies associated with potassium channelopathies. Epilepsia. 2024. doi:10.1111/epi.18066
BibTeX
@article{Singh2024,
author = {Singh, Veronica and Auerbach, David S},
title = {Neurocardiac pathologies associated with potassium channelopathies},
journal = {Epilepsia},
year = {2024},
doi = {10.1111/epi.18066}
}
EUVIMED